| Typicality: | 0.578 |
| Saliency: | 0.390 |
| from the research phase of development | 6 | temporal |
| from conception | 5 | temporal |
| as a prescription drug | 5 | manner |
| drug → go to → market | 51 |
| drug → go to → the market | 5 |
| negative | neutral | positive |
| 0.289 | 0.582 | 0.129 |
| Raw frequency | 56 |
| Normalized frequency | 0.390 |
| Modifier score | 1.000 |
| Perplexity | 162.004 |